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Molecular-genetic imaging provides visualization in space and
time of normal as well as abnormal cellular processes at a
molecular-genetic level. Molecular imaging has its roots in
molecular biology and cell biology as well as in imaging technol-
ogy and chemistry. Three different noninvasive in vivo imaging
technologies have developed more or less in parallel: (1) mag-
netic resonance (MR) imaging (Ichikawa et al., 2002); (2)
nuclear imaging (QAR, γ camera, and PET) (Blasberg and
Gelovani Tjuvajev, 2002); (3) optical imaging of small animals
(Edinger et al., 2002). There are some new and very exciting
developments in in vivo optical imaging (Weissleder and
Ntziachristos, 2003), including two-photon fluorescent imaging
of viable cells, small organisms, and embryos (Hadjantonakis et
al., 2002). It is the convergence of the imaging and
molecular/cell biology disciplines that is at the heart of this suc-
cess story and is the wellspring for further advances in this new
field. The development of versatile and sensitive noninvasive
assays that do not require tissue samples will be of consider-
able value for monitoring molecular-genetic and cellular
processes in animal models of human disease, as well as for
studies in human subjects in the future. Imaging molecular-
genetic and cellular processes will compliment established
molecular-biological assays that are invasive and require tissue
sampling, and imaging can provide a spatial as well as temporal
dimension to our understanding of various diseases.
We have identified three molecular imaging strategies—
“direct,” “indirect,” and “surrogate”—and the reader is referred to
the following reviews for greater details (Blasberg and Gelovani,
2003) and other perspectives on molecular imaging (Gambhir,
2002; Contag and Ross, 2002; Weissleder, 2002). Direct molec-
ular imaging can be defined in terms of “molecular tracer”-target
interactions, whereby the resultant image of probe localization
and magnitude (image intensity) is directly related to its interac-
tion with the target epitope or enzyme. This strategy has been
established using MR, nuclear and optical imaging technology.
Imaging cell surface-specific antigens or epitopes with radiola-
beled antibodies and genetically engineered antibody frag-
ments (e.g., minibodies) provides examples of direct molecular
imaging that has evolved over the past 30 years. In vivo imaging
of receptor density/occupancy using small radiolabeled molecu-
lar probes has also been widely used, particularly in neuro-
science research, over the past two decades. These examples
represent some of the first molecular imaging applications used
in clinical nuclear medicine research.
More recent research has focused on
chemistry and the synthesis of small
radiolabeled or florescent probes that
target specific receptors (e.g., the estro-
gen or androgen receptors) and flores-
cent probes that are activated by endogenous proteases (Jaffer
et al., 2002). The α(v)β3 integrin is highly expressed on tumor
vasculature and plays an important role in metastasis and
tumor-induced angiogenesis; initial studies on the targeting and
imaging of the α(v)β3 integrin with radiolabeled glycosylated
RGD-containing peptides are very encouraging (Figure 1)
(Haubner et al., 2001). Antisense and aptomer oligonucleotide
probes that specifically hybridize to target mRNA or proteins
have been constructed and studied in vivo. Although some effi-
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Figure 1. Noninvasive imaging of Avβ3 expres-
sion
Transaxial PET images of nude mice bearing
human melanoma xenografts. Images were
acquired 90 min after injection of approximate-
ly 5.5 MBq of (18F)Galacto-RGD. The top left
image shows selective accumulation of the
tracer in the avb3-positve (M21) tumor on the
left flank. No focal tracer accumulation is visible
in the avβ3-negative (M21-L) control tumor
(bottom left image). The three images on the
right were obtained from serial (18F)Galacto-
RGD PET studies in one mouse. These images
illustrate the dose-dependent blockade of trac-
er uptake by the avβ3-selective cyclic
pentapeptide cyclo (-Arg-Gly-Asp-D-Phe-Val-).
Figure adapted from Haubner et al., 2001, with
permission from Cancer Res.
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cacy for γ camera and PET imaging endogenous gene expres-
sion using RASONs has been reported, RASON imaging has
several serious limitations (Blasberg and Gelovani Tjuvajev,
2002).
Indirect imaging strategies are more complex because they
involve pretargeting components that function as molecular-
genetic sensors. One example of indirect imaging that is now
being widely used is reporter gene imaging. In vivo reporter
gene imaging is currently most widely used in radionuclide-
based and optical-based studies, and to a lesser degree with
MR imaging. Most reporter imaging paradigms couple a
reporter gene with a complimentary reporter probe. Imaging the
level of reporter gene product activity through the level of probe
accumulation or level of emitted light provides indirect informa-
tion that reflects the level of reporter gene expression, and the
level of endogenous signaling and transcription factors that
drive reporter gene expression. Reporter transgenes can
encode for an enzyme (e.g., HSV1-tk), a receptor (e.g., hD2R
and hSSTR2), a transporter (e.g., hNIS),
or an antigen as shown in Figure 2A. A
general paradigm for gene imaging using
radiolabeled probes was initially
described in 1995 (Tjuvajev et al., 1995)
and is shown diagrammatically for the
HSV1-tk/GFP dual modality (nuclear +
optical) reporter in Figure 1B. Wild-type
HSV1-tk (Tjuvajev et al., 1998) or a
mutant HSV1-tk gene, HSV1-sr39tk
(Gambhir et al., 2000), are the reporter
genes, and the complementary radiola-
beled probes, (124I)-FIAU and (18F)-FHBG, are most
commonly used in current molecular imaging studies.
Imaging endogenous biological processes
Imaging the transcriptional regulation of endogenous genes or
the activity of specific signaling pathways in living animals (and
potentially in human subjects) using noninvasive imaging tech-
niques can provide a better understanding of normal and dis-
ease-related biological processes. Two recent papers from our
group showed that p53-dependent gene expression and acti-
vated NFAT (nuclear factor of activated T cells) can be imaged
in vivo with PET, and by in situ and in vivo fluorescence
(Doubrovin et al., 2001; Ponomarev et al., 2001). In these stud-
ies, the transcription of the reporter gene (a viral thymidine
kinase and green fluorescent fusion gene, HSV1-tk/GFP) was
inducible and regulated by upstream response elements sensi-
tive to endogenous p53 and NFAT (activated transcription fac-
tors), respectively. However, imaging endogenous gene
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Figure 2. Schematic of different reporter genes
and gene products, and dual modality imaging
of HSV1-tk/GFP reporter gene expression
A illustrates that different reporter genes have
been developed, and the reporter gene prod-
ucts include enzymes (HSV1-tk, HSV1-sr39tk, fire-
fly and Renilla luciferases), transporters (hNIS),
receptors (hSSTR2, hD2R), cell surface antigens
and proteins, and fluorescent proteins (eGFP,
mRFP). Different reporter probes corresponding
to specific reporter genes have also been
developed and used for nuclear (PET), magnet-
ic resonance (MR), and optical (fluorescence
and bioluminescence) imaging as described
and referenced in the text.
B illustrates the steps involved for dual modality
imaging of HSV1-tk/GFP reporter gene expres-
sion. The HSV1-tk/GFP fusion gene is transfected
into target cells by a vector. Inside the transfect-
ed cell, the gene is transcribed to mRNA and
then translated to a fusion protein, HSV1-
TK/GFP, that retains both HSV1-TK enzymatic
activity and GFP fluorescence. After administra-
tion of a radiolabeled probe (e.g., (124I)-FIAU or
(18F)-FHBG) and its transport into the cell, the
probe is phosphorylated by the HSV1-TK com-
ponent of the reporter gene product. The phos-
phorylated radiolabeled probe does not readily
cross the cell membrane and is “trapped” with-
in the cell. Thus, the magnitude of probe accu-
mulation in the cell (level of radioactivity)
reflects the level of HSV1-TK enzyme activity and
level of HSV1-tk gene expression. The GFP com-
ponent of the reporter gene product retains flu-
orescence and can be used for in vivo and in
situ imaging as well as FACS analysis of trans-
duced tumor cells.
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expression may be limited when weak promoters in their usual
Cis-configuration are activated and used to induce reporter
gene expression. This can result in low transcriptional activity of
the reporter gene and a low or nondetectable level of probe
accumulation. To address this issue and enhance the transcrip-
tional activity of the androgen-responsive prostate-specific anti-
gen promoter (PSE), a two-step transcriptional amplification
(TSTA) approach was developed to amplify expression of firefly
luciferase and mutant herpes simplex virus type 1 thymidine
kinase (HSV1-sr39tk) in a prostate cancer cell line (LNCaP)
(Iyer et al., 2001). In another study, methods to enhance the
transcriptional activity of the carcinoembryonic antigen (CEA)
promoter using a trans-system (similar to the TSTA described
above) were used to selectively treat and image CEA-express-
ing tumors (Qiao et al., 2002). Gene expression levels are also
regulated by posttranscriptional modulation, including the trans-
lation of mRNA. A recent study demonstrated that imaging post-
transcriptional regulation of gene expression is feasible (Figure
3) (Mayer-Kuckuk et al., 2002). This was shown by exposing
cells to antifolates and inducing a rapid increase in the levels of
the enzyme dihydrofolate reductase (DHFR). The DHFR
enzyme binds to its own mRNA in the coding region, and inhibi-
tion of DHFR by antifolate treatment
releases the DHFR enzyme from the
mRNA; consequently, this release
results in an increase in translation of
DHFR protein. This adaptive cellular
response mechanism could be used to
determine whether posttranscriptional
regulation of gene expression could be
monitored by reporter-PET imaging.
Several recent studies have shown that it
is possible to image protein-protein inter-
actions in vivo using PET and optical
techniques (Ray et al., 2002, Luker et al.,
2002), as well as MR (Perez et al., 2002).
These initial results are very encourag-
ing, but at the same time they demon-
strate only constitutive interactions of the
known pairs of interacting proteins.
Further studies will be required to vali-
date the approach with respect to the
sensitivity and dynamic range of these
reporter systems for monitoring the induction and inhibition of
endogenous protein-protein interactions.
Monitoring vector targeting and gene therapy
A noninvasive, clinically applicable method for imaging the
expression of successful gene transduction in target tissue or
specific organs of the body would be of considerable value for
monitoring and evaluating gene therapy in human subjects
(Jacobs et al., 2001; Blasberg and Gelovani Tjuvajev, 2002).
Noninvasive imaging techniques using selected reporter gene
and reporter probe combinations can provide a practical and
clinically useful way to identify successful gene transduction
and to monitor the level of gene expression over time in patients
undergoing gene therapy. Several vector reporter gene para-
digms have been developed for optical and nuclear imaging.
Many of these paradigms provide the ability to repeatedly
assess gene expression over time, especially when multiple
sequential biopsies are not feasible. The absence of any pertur-
bation of the underlying tissue which occurs with biopsy proce-
dures, and the ability to obtain 3D spatial information in the
entire body as well as target organs and tumors repeatedly over
time, will be of considerable value when addressing toxicity
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Figure 3. Posttranscriptional regulation of gene
expression
Schematic representation of the retroviral vec-
tor used for imaging; the retroviral vector codes
for the DHFR-HSV1TK fusion protein (A). Western
blot analysis using an anti-DHFR antibody shows
increased DHFR-HSV1TK fusion protein levels in
various transduced and parental colon cancer
cells exposed to antifolate (1 µM TMTX or MTX)
for 24 hr (B). PET images obtained in DHFR-
HSV1tk transduced xenograft-bearing rats, 24 hr
after i.v. (124I) FIAU administration (260 µCi/rat)
following treatment with TMTX (10 mg/kg × 3
days or 100 mg/kg single dose) or saline (C). A
1.5- to 4-fold increase in reporter expression was
observed in the antifolate-treated animals,
demonstrating a significant level of posttran-
scriptional regulation DHFR-HSV1TK. Figure
adapted from Mayer-Kuckuk et al., 2002, with
permission from Proc. Natl. Acad. Sci. USA.
330 CANCER CELL : APRIL 2003
issues. Noninvasive imaging will become more important in the
assessment and validation of new tissue-specific and pretarget-
ed viral and nonviral gene delivery vectors following systemic as
well as local routes of administration. The ability to repeatedly
image over time will provide information on the biodistribution
and pharmacokinetics of these novel vectors, and will facilitate
the translation and application of these vectors in clinical studies.
Imaging cell trafficking, adoptive therapy, and tumor
development
Reporter-gene imaging is also being used to visualize adoptive-
ly transferred cells (e.g., T lymphocytes and stem/progenitor
cells) as well as the growth and metastasis of orthotopic and
transgenic tumors. Genetically labeled cells have been used
previously for monitoring adoptive therapy, and this dates back
to the late 1980’s, where reporter gene expression was detect-
ed by PCR or FACS analysis of peripheral blood. However, visu-
alization and quantification of the in vivo distribution of infused
cells in the body over time cannot be addressed by this
approach. Several elegant imaging studies of T cell trafficking
have used MR (Zhao et al., 2002), optical (Mandl et al., 2002),
and nuclear (Dubey et al., 2003; Koehne et al., 2003) imaging
technology. MR achieves better resolution, PET is better for
quantitation, and optical is most cost effective in small animals.
Similar approaches have been used to image orthotopic tumor
growth and metastases and transduced cardiac tissue, as well
as the endogenous development of tumors in transgenically
altered mice (Vooijs et al., 2002).
Drug discovery and monitoring response
Increasing insights into the genetics and molecular biology of
cancer have resulted in the identification of a large number of
potential molecular targets for anticancer drug discovery and
development. These targets can be approached through
exploitation of emerging structural biology, “rational” drug
design, screening of chemical libraries, or a combination of
these methods. Based on analyses of
structures of key signaling proteins,
secondary structure peptidomimetic
approach is a rational way to develop
novel therapeutic agents. The identifica-
tion of biologically significant pep-
tidomimetic structures has led to several
nonpeptide pharmaceuticals. In recent
years, the pharmaceutical industry has
become adept at developing effective inhibitors of protein kinas-
es. A most impressive example of such inhibitors in the clinic
has been imatinib (Gleevec)—the inhibitor of BCR–ABL that
has provided a great leap forward in the treatment of chronic
myeloid leukaemia and gastrointestinal stromal tumors.
Inhibitors of other growth factor receptor (GFR) kinases that are
involved in several signaling pathways have been under devel-
opment for some time, and many have now entered clinical tri-
als. At least six small molecule inhibitors of EGFR tyrosine
kinase activity are now in clinical trials. The two drugs in this
class that are at the most advanced stage of development are
ZD1839 (Iressa) from AstraZeneca and OSI-774 (Tarceva) from
OSI/Genentech.
Recent attempts to develop several radiolabeled 4-(anili-
no)quinazoline derivatives as molecular tracers for imaging
EGFR kinase occupancy/activity have been reported (Ortu et
al., 2002) and illustrate the general failure of approaches that
attempt to radiolabel therapeutic compounds in order to obtain
“imageable” EGFR kinase-specific tracers. The failure to obtain
meaningful images of EGFR expression/activity are related to
(1) the high lipophilicity of the compounds (LogP > 3.5), which
results in rapid clearance of these radiotracers from blood and
redistribution in the body (depot effect); (2) the predominantly
hepato-biliary, rather than renal clearance, of these lipophylic
tracers; (3) the absence of a specific signal and high back-
ground activity during image acquisition (the relatively short
half-life of the radionuclides used for labeling of these tracers,
11C–20 min and 18F–110 min, precludes the use of a “washout
strategy” [Tjuvajev et al., 1994]); (4) the position of the radionu-
clide in the chemical structure of the tracer is important with
respect to the clearance of radiolabeled metabolites.
Derivatization and radiolabeling of therapeutic compounds with
more suitable pharmacokinetics for targeting EGFR kinase and
PET imaging should consider the following: (1) compound
lipophilicity (e.g., 0.8 < LogP <1.5); (2) resistance to metabolic
degradation; (3) predominantly renal clearance; (4) “irreversible”
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Figure 4. FDG PET imaging before and 24 hr after
treatment
In patients with gastrointestinal stromal tumors
(GIST), tumor glucose utilization is very high and
these tumors can be readily visualized by (18F)-
fluorodeoxyglucose (FDG) positron emission
tomography (PET). A striking observation in
patients with GIST who are treated with STI571
(Gleevec) is the rapid and sustained decrease
in fluorodeoxyglucose (FDG) uptake deter-
mined by PET scan. For the patient shown here,
a 55% decrease was seen as early as 24 hr fol-
lowing one dose of STI571, and this was sus-
tained over 15 months. The high FDG levels seen
in the heart, kidney, and bladder are normal in
both the pre- and post-Gleevec images. Figure
adapted from Demetri et al., 2002, with permis-
sion from N. Engl. J. Med.
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binding to the EGFR kinase ATP-binging domain to ensure that
the half-life of probe-target complex is substantially longer than
that for elimination of nonspecifically accumulated radioactivity.
Successful imaging of EGFR or other GFR kinase expres-
sion/activity should be possible following optimization of EGFR
kinase-specific tracers.
The development of molecular imaging approaches to
assess the level of expression of specific signaling proteins and,
most importantly, the level of signaling activity would have sig-
nificant clinical impact. The pre-selection of patients based on
high levels of drug-target expression, suggesting a higher
potential sensitivity to the given drug, is feasible. In addition,
repetitive imaging during the course of therapy would allow for
monitoring target activity during dose escalation studies and
could provide unique information to determine the optimum
dose of drug for target inhibition in individual patients. Variants
of these approaches have been investigated with all three imag-
ing modalities.
Alternatively, “surrogate” imaging can reflect the down-
stream effects of one or more endogenous molecular/genetic
processes. This is particularly attractive for potential translation
into clinical studies in the near term, since direct and indirect
molecular imaging studies are only beginning to be implement-
ed in the clinic (Jacobs et al., 2001). Existing radiopharmaceuti-
cals and imaging paradigms are gaining increasing attention,
particularly as they relate to the development and testing of new
pathway-specific drugs. The translation of surrogate-marker
imaging paradigms into patients will be far easier than either the
reporter transgene or direct imaging paradigms outlined above.
Nevertheless, it remains to be shown whether there is a suffi-
ciently high correlation between surrogate imaging and direct
molecular assays that reflect the activity of a particular molecu-
lar/genetic pathway of interest. The assessment of noncytotox-
ic, cytostatic drugs, such as the antiangiogenic class of drugs,
pose particular problems for treatment assessments that are
based on imaging tumor volume. Imaging of tumor vascularity is
being proposed as a surrogate assessment of antiangiogenesis
treatment response. Another example of a clinically useful sur-
rogate is FDG imaging for the assessment of early treatment
response, prior to tumor volume changes. This was shown dra-
matically for gastrointestinal stromal tumors (GIST) pre- and 24
hr post-STI571 (Gleevec) treatment (Figure 4) (Demetri et al.,
2002); similar pre- and post-treatment FDG images have been
shown for other solid tumors (e.g., lymphomas). Whether imag-
ing surrogate markers will be of value for assessing treatment
directed at other molecular/genetic abnormalities in tumors
(EGFR, p53, c-Met, HIF-1, etc.) remains to be demonstrated.
Translation of reporter imaging paradigms to patients
The major factor limiting translation of reporter gene imaging
studies to patients is the transduction requirement; target tissue
must be transduced with the reporter constructs for reporter
gene imaging studies. At least two different reporter constructs
will be required in most cases; one will be a “constitutive”
reporter that will be used to identify the site, extent and duration
of vector delivery, and tissue transduction (the normalizing or
denominator term), and one will be an “inducible” reporter that is
sensitive to endogenous transcription factors, signaling path-
ways, or protein-protein interactions, as described above. The
initial application of such double-reporter systems in patients will
most likely be performed as part of a gene therapy protocol
(Jacobs et al., 2001) or an adoptive therapy protocol where the
patients own cells are harvested (e.g., lymphocytes, T cells, or
blood-derived progenitor cells) and can be transduced and
expanded ex vivo, and then adoptively readministered to the
patient. This scenario couples reporter gene imaging with exist-
ing adoptive therapies and allows for ex vivo transduction and
expansion of harvested cells. For example, adoptive T cell thera-
py could provide a venue for imaging T cell trafficking, targeting,
activation, proliferation, and persistence (Ponomarev et al.,
2001; Koehne et al., 2003). This imaging paradigm could
address several important questions related to adoptive T cell
therapies. For example, is there substantial proliferation of adop-
tively transferred T cells at the target site or does activation and
proliferation occur at other sites (e.g., specific lymphoid organ
sites), followed by migration and localization to the target site?
This question could potentially be addressed in a quantitative
manner by repetitive PET imaging of the double-reporter system
described above in the same animal or subject over time.
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